Clinical trial
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes…
NCT00453401 · NanoBio Corporation, Industry · Completed
Key facts
| NCT number | NCT00453401 |
|---|---|
| Title | Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis |
| Official title | The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis |
| Lead sponsor | NanoBio Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Herpes Labialis |
| Intervention type | Drug |
| Interventions | NB-001 |
| Enrollment | 1,000 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 28, 2007 |
| Last update posted | May 30, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: